Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid vs Linezolid in ABSSSI
NCT02066402Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of tedizolid in acute bacterial skin and skin structure infections (ABSSSI), sponsored by Bayer. Started Mar 2014; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02066402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066402.